Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 444

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730)

Lilenbaum, Rogerio C., Herndon, James E., List, Marcy A., Desch, Chris, Watson, Dorothy M., Miller, Antonius A., Graziano, Stephen L., Perry, Michael C., Saville, Wayne, Chahinian, Philippe, Weeks, Jane C., Holland, Jimmie C., Green, Mark R.·2005·Journal of Clinical Oncology

Abstract

Purpose: We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non–small-cell lung cancer. Patients and Methods: A total of 561 eligible patients were randomly assigned to receive paclitaxel alone or in combination with carboplatin. Results: The response rate was 17% in the paclitaxel arm and 30% in the carboplatin-paclitaxel arm (P < .0001). Median failure-free survival was 2.5 months in the paclitaxel arm and 4.6 months in the carboplatin-paclitaxel arm (P = .0002). Median survival times were 6.7 months (95% CI, 5.8 to 7.8) and 8.8 months (95% CI, 8.0 to 9.9), and 1-year survival rates were 32% (95% CI, 27% to 38%), and 37% (95% CI, 32% to 43%), respectively. The overall survival distributions were not statistically different: hazard ratio = 0.91 (95% CI, 0.77 to 1.17; P = .25). Hematological toxicity and nausea were more frequent in the combination arm, but febrile neutropenia and toxic deaths were equally low in both arms. There was no significant survival difference in elderly patients. Performance status 2 patients treated with combination chemotherapy had a better survival rate than those treated with single-agent therapy (P = .019). Conclusion: Combination chemotherapy improves response rate and failure-free survival compared with single-agent therapy, but there was no statistically significant difference in the primary end point of overall survival. The results in elderly patients were similar to younger patients. Performance status 2 patients had a superior outcome when treated with combination chemotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.07.172

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 444

Metadata

Authors
Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P., Weeks, J. C., Holland, J. C., & Green, M. R.
Venue
Journal of Clinical Oncology
Published
2005-01-01
Volume
23
Issue
1
Pages
190-196
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2160131381
Cited by
444
References
13
FWCI
27.85
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730). https://app.cochat.ai/papers/10.1200/jco.2005.07.172
The paper
Lilenbaum, R. C., Herndon, J. E., List, M. A., Desch, C., Watson, D. M., Miller, A. A., Graziano, S. L., Perry, M. C., Saville, W., Chahinian, P., Weeks, J. C., Holland, J. C., & Green, M. R. (2005). Single-Agent Versus Combination Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.07.172

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.